These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9024268)

  • 1. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus.
    Andersson B; Mattsson LA; Hahn L; Mårin P; Lapidus L; Holm G; Bengtsson BA; Björntorp P
    J Clin Endocrinol Metab; 1997 Feb; 82(2):638-43. PubMed ID: 9024268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of continuous combined HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diabetes.
    Thunell L; Andersson B; Glassell M; Mattsson LA
    Maturitas; 2006 Mar; 53(4):430-8. PubMed ID: 16198072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial.
    Andersson B; Johannsson G; Holm G; Bengtsson BA; Sashegyi A; Pavo I; Mason T; Anderson PW
    J Clin Endocrinol Metab; 2002 Jan; 87(1):122-8. PubMed ID: 11788634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
    Araújo DA; Farias ML; Andrade AT
    Climacteric; 2002 Sep; 5(3):286-92. PubMed ID: 12419087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of oestrogen replacement therapy on haemostatic variables in postmenopausal women with non-insulin-dependent diabetes mellitus.
    Hahn L; Mattsson LA; Andersson B; Tengborn L
    Blood Coagul Fibrinolysis; 1999 Mar; 10(2):81-6. PubMed ID: 10192656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does androgen excess contribute to the cardiovascular risk profile in postmenopausal women with type 2 diabetes?
    Korytkowski MT; Krug EI; Daly MA; Deriso L; Wilson JW; Winters SJ
    Metabolism; 2005 Dec; 54(12):1626-31. PubMed ID: 16311096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of methyltestosterone postmenopausal therapy on plasma lipids, inflammatory factors, glucose metabolism and visceral fat: a randomized study.
    Leão LM; Duarte MP; Silva DM; Bahia PR; Coeli CM; de Farias ML
    Eur J Endocrinol; 2006 Jan; 154(1):131-9. PubMed ID: 16382002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM.
    Brussaard HE; Gevers Leuven JA; Frölich M; Kluft C; Krans HM
    Diabetologia; 1997 Jul; 40(7):843-9. PubMed ID: 9243107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
    Oleksik AM; Duong T; Pliester N; Asma G; Popp-Snijders C; Lips P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2763-8. PubMed ID: 11397884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of transdermal estrogen replacement therapy on hyperandrogenicity and glucose homeostasis in postmenopausal women with NIDDM.
    Andersson B; Mattsson LA
    Acta Obstet Gynecol Scand; 1999 Mar; 78(3):260-1. PubMed ID: 10078591
    [No Abstract]   [Full Text] [Related]  

  • 11. The effects of sequential combined oral 17beta-estradiol norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomized single blind placebo-controlled study.
    Walker RJ; Lewis-Barned NJ; Sutherland WH; Goulding A; Edwards EA; de Jong SA; Gold E; Walker HL
    Menopause; 2001; 8(1):27-32. PubMed ID: 11201511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial.
    Franco C; Brandberg J; Lönn L; Andersson B; Bengtsson BA; Johannsson G
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1466-74. PubMed ID: 15598680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on relationship between endogenous androgens and insulin resistance at the different stages of postmenopause].
    Cao YK; Zhang SF; Zou SE; Xia X; Xu LN
    Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):740-4. PubMed ID: 24406129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women.
    Lambrinoudaki I; Christodoulakos G; Rizos D; Economou E; Argeitis J; Vlachou S; Creatsa M; Kouskouni E; Botsis D
    Eur J Endocrinol; 2006 Jun; 154(6):907-16. PubMed ID: 16728552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study.
    Perera M; Sattar N; Petrie JR; Hillier C; Small M; Connell JM; Lowe GD; Lumsden MA
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1140-3. PubMed ID: 11238498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous estrogen and androgen levels are not independent predictors of lipid levels in postmenopausal women.
    Worsley R; Robinson PJ; Bell RJ; Moufarege A; Davis SR
    Menopause; 2013 Jun; 20(6):640-5. PubMed ID: 23531683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.
    Hemelaar M; van der Mooren MJ; Mijatovic V; Bouman AA; Schijf CP; Kroeks MV; Franke HR; Kenemans P
    Menopause; 2003; 10(6):550-8. PubMed ID: 14627865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes.
    Friday KE; Dong C; Fontenot RU
    J Clin Endocrinol Metab; 2001 Jan; 86(1):48-52. PubMed ID: 11231977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.